|1.||Fiorucci, Stefano: 3 articles (09/2004 - 12/2003)|
|2.||Antonelli, Elisabetta: 3 articles (09/2004 - 12/2003)|
|3.||Morelli, Antonio: 3 articles (09/2004 - 12/2003)|
|4.||Morelli, A: 3 articles (05/2003 - 02/2001)|
|5.||Fiorucci, S: 3 articles (05/2003 - 02/2001)|
|6.||Spénard, Jean: 2 articles (01/2011 - 05/2010)|
|7.||Del Soldato, Piero: 2 articles (09/2004 - 12/2003)|
|8.||Distrutti, Eleonora: 2 articles (09/2004 - 12/2003)|
|9.||Antonelli, E: 2 articles (05/2003 - 07/2001)|
|10.||Palazzetti, B: 2 articles (07/2001 - 02/2001)|
01/01/2004 - "Preclinical studies have shown that long- and short-term administration of NCX-1000 to rodents with chronic liver injury protects against the development of portal hypertension and reduces the intrahepatic hyperreactivity to alpha1-adrenoceptor agonists. "
01/01/2004 - "In summary, these data suggest that NCX-1000 may provide a novel therapy for the treatment of patients with portal hypertension."
01/01/2004 - "Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. "
05/01/2003 - "Administration of NCX1000 to portal hypertensive rats decreases intrahepatic resistance providing a novel therapy for the treatment of portal hypertension."
07/17/2001 - "In aggregate these data indicate that NCX-1000, releasing NO into the liver microcirculation, may provide a novel therapy for the treatment of patients with portal hypertension."
|2.||Liver Cirrhosis (Hepatic Cirrhosis)
07/17/2001 - "In this study we have examined the effect of NCX-1000 and UDCA on liver fibrosis and portal hypertension induced by i.p. "
12/01/2003 - "We studied whether acute administration of NCX-1000, a nitric oxide (NO)-releasing derivative of ursodeoxycholic acid (UDCA), to animals with established liver cirrhosis decreases intrahepatic resistance and modulates hepatic vascular hypereactivity to norepinephrine (NE). "
02/27/2001 - "In the present study we provide evidence that a nitric oxide (NO) derivative of ursodeoxycholic acid (UDCA), NCX-1000 ([2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester]), protects against liver damage in murine models of autoimmune hepatitis induced by i.v. injection of Con A or a Fas agonistic antibody, Jo2. "
05/01/2010 - "In patients with cirrhosis and portal hypertension, NCX-1000 administration was safe, but it was not able to reduce portal pressure. "
05/01/2010 - "NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study."
05/01/2010 - "NCX-1000 (2(acetyloxy) benzoic acid-3(nitrooxymethyl)phenyl ester) is an nitric oxide (NO)-releasing derivative of ursodeoxycholic acid (UDCA), which showed selective vasodilatory effect on intrahepatic circulation in animal models of cirrhosis. "
|5.||Acute Liver Failure (Fulminant Hepatic Failure)
03/01/2009 - "Notice of Retraction: 'Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice' (Br J Pharmacol 143; 33-42; 2004)."
09/01/2004 - "Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice."
|1.||Nitric Oxide (Nitrogen Monoxide)
|2.||Ursodeoxycholic Acid (Urso)
|4.||Benzoic Acid (Ucephan)